Meridian's second cohort clears a clean month with the first file still sealed

The second cohort of Meridian's longevity protocol finished a full month this week with clean biomarkers and no reported harm. Two hundred eight people walked out of the dosing rooms looking, by every panel the colony chose to publish, younger than the calendar says they are. The directorate announced the milestone the way one announces a verdict already reached. Ask who ages first, and here is your answer: whoever books the ticket.

The numbers are, on their own terms, reassuring. Three cohorts. Four hundred seventeen people. No published adverse events. A fourth cohort of 139 paying passengers is scheduled to ship in sixty-one days, transfer window permitting, and the roster is full. The framework that Earth's longevity therapy board and Meridian's directorate signed this week promises a shared dataset for all of them: cohort biomarkers, dosing schedules, observation windows, agreed definitions of what counts as harm. On paper it is the most transparency Earth has ever pried loose from an independent colony.

And yet.

The framework opens every cohort but the one that mattered. Meridian retained, in writing, the unilateral right to classify individual files. It has used that right exactly once, on a nine-page medical record from the first cohort of 140. The record describes a retired desalination engineer who ran an unexplained fever the protocol cannot account for. Earth's board has asked for it four times. Meridian has refused four times. The clean month the directorate celebrated this week doesn't touch it, because the fever belongs to a cohort the framework doesn't cover.

So let's ask the questions the directorate would rather we didn't. What does a transparency deal transmit if it seals the single document its auditors requested by name? What is an observation window worth if the observers may draw the curtain on any window they choose? Who benefits when a program can point to 417 clean records while classifying the one that isn't?

Earth's regulators spent the week discovering the limits of a victory they thought they'd won. The board has never independently inspected a Meridian dosing room. It has never handled a biomarker panel that Meridian didn't first prepare. It has never seen the fever file it has requested four times. Its audit authority, on close reading, extends only to the data the directorate volunteers. "We hold the right to review what we are given," one board member said, declining to be named while the framework's terms are still being ratified. "We are asking what happens when what we are given is chosen for us."

My colleague Beatriz Salgado put the arithmetic plainly on this desk: the deal opens every future cohort and seals the one that mattered. Meridian's directorate calls that sovereignty. The engineer's fever, whatever it was, remains a fact recorded on nine pages that no one outside the colony has been allowed to read. Requested four times. Refused four times. And now, by the framework's own terms, refusable forever.